Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 10;12:5781–5795. doi: 10.2147/IJN.S140179

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Shi et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

HAPs suppress angiogenesis through the inhibition of PI3K/Akt-dependent eNOS/NO pathway.

Notes: The expression profile of key proteins in the PI3K/Akt/eNOS pathway in HUVECs cultured with np20 (A1), np80 (A2) and m-HAP (A3) for 24 h. (B) NO levels of HUVECs incubated with HAPs for 24 h. ^*P<0.01 versus control, ^&P<0.01 versus m-HAP group, ^#P<0.05; ^##P<0.01 versus np20 group. Cells without HAPs treatment were set as the control group. (C) NO levels and (D) cell viability of HUVECs exposed to HAPs in the presence or absence of IGF-1, respectively. ^*P<0.05; ^**P<0.01 versus vehicle control.

Abbreviations: HAP, hydroxyapatite; HUVECs, human umbilical vein endothelial cells; m-HAP, micro-sized HAP particles; NO, nitric oxide.